ClinicalTrials.gg
CompletedNCT03945188ELEVATE UC 52Updated Dec 20, 2022Results posted

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of Etrasimod and Placebo in Ulcerative Colitis, sponsored by Arena Pharmaceuticals. Completed at 315 sites in 40 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-12-20.

Sponsored by Arena Pharmaceuticals (part of Pfizer) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
433
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing etrasimod in Colitis, Ulcerative — 3 open to participants now, 5 under way, 2 of them phase 3. etrasimod · Colitis, Ulcerative.

Enrollment
2nd of 12
433 · median 195
Started
2019
with 2 others
Phase 3
5 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
4 of 12
Arena Pharmaceuticals

Among the 12 studies testing etrasimod in Colitis, Ulcerative, this one is the 2nd largest by enrollment, is one of 3 that started in 2019, is one of 5 in phase 3, and was the 3rd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 12 studies testing etrasimod in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About etrasimod

etrasimod: first FDA approval 2023 (VELSIPITY), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 16 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing etrasimod in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Ulcerative Colitis
  • Etrasimod
  • APD334
04

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed with ulcerative colitis (UC) ≥ 3 months prior to screening
  2. Active UC confirmed by endoscopy

Exclusion criteria

Exclusion criteria:

  1. Severe extensive colitis
  2. Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD
  3. Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
433 participants (actual)

Study arms

  • Experimental
    Etrasimod 2 mg

    Drug: Etrasimod

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment

    Also known as: APD334

  • DrugPlacebo

    Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Clinical Remission at Week 12

    Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily eDiary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

    Time frame: At Week 12

  2. Percentage of Participants Achieving Clinical Remission at Week 52

    Clinical remission was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical remission was defined as SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

    Time frame: At Week 52

Secondary outcomes

  1. Percentage of Participants Achieving Endoscopic Improvement at Week 12

    Endoscopic improvement was defined as an ES ≤ 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease).

    Time frame: At Week 12

  2. Percentage of Participants Achieving Endoscopic Improvement at Week 52

    Endoscopic improvement was defined as an ES ≤ 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease).

    Time frame: At Week 52

  3. Percentage of Participants Achieving Symptomatic Remission at Week 12

    Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.

    Time frame: At Week 12

  4. Percentage of Participants Achieving Symptomatic Remission at Week 52

    Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.

    Time frame: At Week 52

  5. Percentage of Participants With Mucosal Healing at Week 12

    Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.

    Time frame: At Week 12

  6. Percentage of Participants With Mucosal Healing at Week 52

    Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.

    Time frame: At Week 52

  7. Percentage of Participants Achieving Corticosteroid-free Clinical Remission at Week 52

    Corticosteroid-free clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, ES ≤ 1 (excluding friability), and have not received corticosteroids for ≥ 12 weeks in the 40-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

    Time frame: At Week 52

  8. Percentage of Participants Achieving Sustained Clinical Remission at Both Weeks 12 and 52

    Sustained clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability) at both Week 12 and Week 52. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

    Time frame: At Weeks 12 and 52

  9. Percentage of Participants Achieving Clinical Response at Week 12

    Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

    Time frame: At Week 12

  10. Percentage of Participants Achieving Clinical Response at Week 52

    Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB sub-score ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

    Time frame: At Week 52

  11. Percentage of Participants Achieving Clinical Response at Both Weeks 12 and 52

    Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

    Time frame: At Weeks 12 and 52

  12. Percentage of Participants With Mucosal Healing at Both Weeks 12 and 52

    Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.

    Time frame: At Weeks 12 and 52

  13. Percentage of Participants Achieving Endoscopic Normalization at Week 12

    Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).

    Time frame: At Week 12

  14. Percentage of Participants Achieving Endoscopic Normalization at Week 52

    Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).

    Time frame: At Week 52

  15. Percentage of Participants Achieving Endoscopic Normalization at Both Weeks 12 and 52

    Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).

    Time frame: At Weeks 12 and 52

  16. Percentage of Participants Achieving Symptomatic Remission by Study Visit

    Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.

    Time frame: At Weeks 2, 4, 8, 16, 20, 24, 32, 40, and 48

  17. Percentage of Participants Achieving Complete Symptomatic Remission by Study Visit

    Complete symptomatic remission was defined as an SF subscore = 0 and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.

    Time frame: At Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48 and 52

  18. Percentage of Participants Achieving Non-invasive Clinical Response by Study Visit

    Non-invasive clinical response was defined as a ≥ 30% decrease from Baseline in composite RB and SF subscores, and a ≥ 1-point decrease from Baseline in RB subscore or RB subscore ≤ 1. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.

    Time frame: At Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52

  19. Percentage of Participants Achieving Symptomatic Response by Study Visit

    Symptomatic response was defined as a ≥ 30% decrease from Baseline in composite RB and SF subscores. The SF subscore ranged from 0 to 3 (where 0= normal number of stools and 3= at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0= no blood and 3= blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.

    Time frame: At Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52

  20. Percentage of Participants Achieving 4-week Corticosteroid-free Clinical Remission at Week 52 Among Participants Receiving Corticosteroids at Baseline

    Four-week corticosteroid-free clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1, and have not received corticosteroids for ≥ 4 weeks in the 40-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

    Time frame: At Week 52

  21. Percentage of Participants Achieving Clinical Remission at Week 52 Among Participants in Clinical Response at Week 12

    Clinical remission and clinical response were based on the MMS which is a composite of 3 assessments: SF, RB and ES. Clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

    Time frame: At Week 52

07

Results

Posted Dec 20, 2022

Participant flow

Participants with moderately to severely active ulcerative colitis (UC) were enrolled in this study. Eligible participants were randomized in a 2:1 ratio to receive either etrasimod 2 milligrams (mg) once daily or matching placebo once daily for up to 52 weeks.

Participant flow — Overall Study
MilestoneEtrasimod 2 mgPlacebo
Started289144
Completed16146
Not completed12898
Withdrew: Protocol violation10
Withdrew: Disease worsening7973
Withdrew: Physician decision22
Withdrew: Lack of efficacy74
Withdrew: Pregnancy20
Withdrew: Withdrawal by participant or parent/guardian2410
Withdrew: Adverse event105
Withdrew: Other22
Withdrew: Lost to follow-up12

Outcome measures

PrimaryPercentage of Participants Achieving Clinical Remission at Week 12

Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily eDiary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Remission at Week 12
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Clinical Remission at Week 1227.07.4
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 19.75 · 95% CI 12.88 to 26.63
PrimaryPercentage of Participants Achieving Clinical Remission at Week 52

Clinical remission was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical remission was defined as SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Remission at Week 52
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Clinical Remission at Week 5232.16.7
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 25.39 · 95% CI 18.42 to 32.36
SecondaryPercentage of Participants Achieving Endoscopic Improvement at Week 12

Endoscopic improvement was defined as an ES ≤ 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease).

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Endoscopic Improvement at Week 12
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Endoscopic Improvement at Week 1235.014.1
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 21.18 · 95% CI 13.03 to 29.32
SecondaryPercentage of Participants Achieving Endoscopic Improvement at Week 52

Endoscopic improvement was defined as an ES ≤ 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease).

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Endoscopic Improvement at Week 52
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Endoscopic Improvement at Week 5237.210.4
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 26.69 · 95% CI 18.99 to 34.39
SecondaryPercentage of Participants Achieving Symptomatic Remission at Week 12

Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Symptomatic Remission at Week 12
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Symptomatic Remission at Week 1246.021.5
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 24.55 · 95% CI 15.46 to 33.63
SecondaryPercentage of Participants Achieving Symptomatic Remission at Week 52

Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Symptomatic Remission at Week 52
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Symptomatic Remission at Week 5243.418.5
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 24.89 · 95% CI 16.17 to 33.60
SecondaryPercentage of Participants With Mucosal Healing at Week 12

Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Mucosal Healing at Week 12
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants With Mucosal Healing at Week 1221.24.4
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 16.88 · 95% CI 10.78 to 22.98
SecondaryPercentage of Participants With Mucosal Healing at Week 52

Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Mucosal Healing at Week 52
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants With Mucosal Healing at Week 5226.68.1
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 18.39 · 95% CI 11.39 to 25.39
SecondaryPercentage of Participants Achieving Corticosteroid-free Clinical Remission at Week 52

Corticosteroid-free clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, ES ≤ 1 (excluding friability), and have not received corticosteroids for ≥ 12 weeks in the 40-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Corticosteroid-free Clinical Remission at Week 52
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Corticosteroid-free Clinical Remission at Week 5232.16.7
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 25.39 · 95% CI 18.42 to 32.36
SecondaryPercentage of Participants Achieving Sustained Clinical Remission at Both Weeks 12 and 52

Sustained clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability) at both Week 12 and Week 52. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

Time frame:
At Weeks 12 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Sustained Clinical Remission at Both Weeks 12 and 52
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Sustained Clinical Remission at Both Weeks 12 and 5217.92.2
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 15.84 · 95% CI 10.66 to 21.03
SecondaryPercentage of Participants Achieving Clinical Response at Week 12

Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Response at Week 12
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Clinical Response at Week 1262.434.1
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 28.27 · 95% CI 18.51 to 38.02
SecondaryPercentage of Participants Achieving Clinical Response at Week 52

Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB sub-score ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Response at Week 52
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Clinical Response at Week 5248.223.0
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 24.93 · 95% CI 15.79 to 34.07
SecondaryPercentage of Participants Achieving Clinical Response at Both Weeks 12 and 52

Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

Time frame:
At Weeks 12 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Response at Both Weeks 12 and 52
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Clinical Response at Both Weeks 12 and 5244.918.5
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 26.16 · 95% CI 17.48 to 34.84
SecondaryPercentage of Participants With Mucosal Healing at Both Weeks 12 and 52

Mucosal healing was defined as an ES ≤ 1 (excluding friability) with histologic remission measured by a Geboes Index score \< 2.0. The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system is a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicates more severe disease.

Time frame:
At Weeks 12 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Mucosal Healing at Both Weeks 12 and 52
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants With Mucosal Healing at Both Weeks 12 and 5213.52.2
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 11.32 · 95% CI 6.49 to 16.14
SecondaryPercentage of Participants Achieving Endoscopic Normalization at Week 12

Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).

Time frame:
At Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Endoscopic Normalization at Week 12
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Endoscopic Normalization at Week 1214.64.4
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 10.23 · 95% CI 4.73 to 15.73
SecondaryPercentage of Participants Achieving Endoscopic Normalization at Week 52

Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Endoscopic Normalization at Week 52
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Endoscopic Normalization at Week 5226.35.9
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 20.39 · 95% CI 13.79 to 26.98
SecondaryPercentage of Participants Achieving Endoscopic Normalization at Both Weeks 12 and 52

Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease).

Time frame:
At Weeks 12 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Endoscopic Normalization at Both Weeks 12 and 52
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Endoscopic Normalization at Both Weeks 12 and 5210.61.5
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 9.16 · 95% CI 4.93 to 13.38
SecondaryPercentage of Participants Achieving Symptomatic Remission by Study Visit

Symptomatic remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline) and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.

Time frame:
At Weeks 2, 4, 8, 16, 20, 24, 32, 40, and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Symptomatic Remission by Study Visit
Percentage of participantsEtrasimod 2 mgPlacebo
Week 215.38.9
Week 428.113.3
Week 837.620.7
Week 1643.121.5
Week 2043.820.0
Week 2444.923.7
Week 3244.518.5
Week 4042.018.5
Week 4842.015.6
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.049 · Risk difference (rd): 6.49 · 95% CI 0.02 to 12.95
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 15.03 · 95% CI 7.32 to 22.74
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 16.85 · 95% CI 8.06 to 25.63
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 21.66 · 95% CI 12.71 to 30.61
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 23.74 · 95% CI 14.98 to 32.51
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 21.04 · 95% CI 11.83 to 30.24
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 25.82 · 95% CI 17.08 to 34.56
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 23.47 · 95% CI 14.80 to 32.14
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 26.37 · 95% CI 17.92 to 34.82
SecondaryPercentage of Participants Achieving Complete Symptomatic Remission by Study Visit

Complete symptomatic remission was defined as an SF subscore = 0 and RB subscore = 0. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicate more severe disease.

Time frame:
At Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Complete Symptomatic Remission by Study Visit
Percentage of participantsEtrasimod 2 mgPlacebo
Week 25.82.2
Week 411.34.4
Week 816.86.7
Week 1223.06.7
Week 1621.25.9
Week 2022.34.4
Week 2422.38.1
Week 3223.03.0
Week 4021.25.9
Week 4819.72.2
Week 5224.54.4
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.057 · Risk difference (rd): 3.59 · 95% CI -0.11 to 7.30
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.007 · Risk difference (rd): 6.88 · 95% CI 1.86 to 11.90
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.001 · Risk difference (rd): 10.14 · 95% CI 4.09 to 16.20
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 16.36 · 95% CI 9.89 to 22.83
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 15.37 · 95% CI 9.23 to 21.52
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 17.80 · 95% CI 11.85 to 23.75
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 14.24 · 95% CI 7.45 to 21.04
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 20.03 · 95% CI 14.25 to 25.81
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 15.13 · 95% CI 8.91 to 21.35
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 17.52 · 95% CI 12.16 to 22.87
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 19.86 · 95% CI 13.75 to 25.98
SecondaryPercentage of Participants Achieving Non-invasive Clinical Response by Study Visit

Non-invasive clinical response was defined as a ≥ 30% decrease from Baseline in composite RB and SF subscores, and a ≥ 1-point decrease from Baseline in RB subscore or RB subscore ≤ 1. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.

Time frame:
At Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Non-invasive Clinical Response by Study Visit
Percentage of participantsEtrasimod 2 mgPlacebo
Week 238.333.3
Week 456.239.3
Week 863.143.0
Week 1265.742.2
Week 1655.530.4
Week 2057.328.1
Week 2456.630.4
Week 3254.025.2
Week 4051.523.0
Week 4851.121.5
Week 5250.423.7
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.336 · Risk difference (rd): 4.83 · 95% CI -5.01 to 14.68
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 17.11 · 95% CI 7.06 to 27.15
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 20.17 · 95% CI 10.15 to 30.19
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 23.44 · 95% CI 13.45 to 33.43
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 25.25 · 95% CI 15.67 to 34.83
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 29.20 · 95% CI 19.77 to 38.64
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 26.08 · 95% CI 16.47 to 35.69
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 28.68 · 95% CI 19.35 to 38.02
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 28.43 · 95% CI 19.30 to 37.55
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 29.59 · 95% CI 20.55 to 38.64
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 26.43 · 95% CI 17.18 to 35.68
SecondaryPercentage of Participants Achieving Symptomatic Response by Study Visit

Symptomatic response was defined as a ≥ 30% decrease from Baseline in composite RB and SF subscores. The SF subscore ranged from 0 to 3 (where 0= normal number of stools and 3= at least 5 stools more than normal) and RB subscore ranged from 0 to 3 (where 0= no blood and 3= blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.

Time frame:
At Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Symptomatic Response by Study Visit
Percentage of participantsEtrasimod 2 mgPlacebo
Week 239.433.3
Week 457.340.0
Week 864.643.7
Week 1266.442.2
Week 1655.531.1
Week 2057.728.1
Week 2456.930.4
Week 3254.725.2
Week 4051.823.0
Week 4851.521.5
Week 5250.723.7
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.240 · Risk difference (rd): 5.93 · 95% CI -3.96 to 15.81
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 17.50 · 95% CI 7.48 to 27.53
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 20.93 · 95% CI 10.92 to 30.94
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 24.13 · 95% CI 14.15 to 34.10
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 24.51 · 95% CI 14.89 to 34.13
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 29.57 · 95% CI 20.13 to 39.01
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 26.45 · 95% CI 16.88 to 36.02
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 29.35 · 95% CI 20.01 to 38.68
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 28.83 · 95% CI 19.71 to 37.95
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 30.00 · 95% CI 20.97 to 39.03
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 26.84 · 95% CI 17.60 to 36.07
SecondaryPercentage of Participants Achieving 4-week Corticosteroid-free Clinical Remission at Week 52 Among Participants Receiving Corticosteroids at Baseline

Four-week corticosteroid-free clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1, and have not received corticosteroids for ≥ 4 weeks in the 40-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving 4-week Corticosteroid-free Clinical Remission at Week 52 Among Participants Receiving Corticosteroids at Baseline
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving 4-week Corticosteroid-free Clinical Remission at Week 52 Among Participants Receiving Corticosteroids at Baseline31.07.5
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 23.05 · 95% CI 10.20 to 35.90
SecondaryPercentage of Participants Achieving Clinical Remission at Week 52 Among Participants in Clinical Response at Week 12

Clinical remission and clinical response were based on the MMS which is a composite of 3 assessments: SF, RB and ES. Clinical remission was defined as an SF subscore = 0 (or = 1 with a ≥ 1-point decrease from Baseline), RB subscore = 0, and ES ≤ 1 (excluding friability). Clinical response was defined as a ≥ 2-point and ≥ 30% decrease from Baseline MMS, and a ≥ 1-point decrease from Baseline in RB subscore or an absolute RB subscore ≤ 1. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

Time frame:
At Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Remission at Week 52 Among Participants in Clinical Response at Week 12
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Clinical Remission at Week 52 Among Participants in Clinical Response at Week 1249.117.4
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 31.86 · 95% CI 18.45 to 45.28

Adverse events

Collected over Up to 56 weeks (12-Week and 40-Week Treatment Periods plus Follow-up). Treatment-emergent adverse events (TEAEs) were collected from first dose of study treatment up to 30 days following discontinuation of the study treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Etrasimod 2 mg0/289 (0%)20/289 (6.9%)204/289 (70.6%)
Placebo0/144 (0%)9/144 (6.3%)77/144 (53.5%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventEtrasimod 2 mgPlacebo
Colitis ulcerativeGastrointestinal disorders6/2893/144
Large intestine perforationGastrointestinal disorders0/2891/144
COVID-19 pneumoniaInfections and infestations1/2891/144
COVID-19Infections and infestations1/2891/144
Campylobacter infectionInfections and infestations0/2891/144
CellulitisInfections and infestations0/2891/144
AnaemiaBlood and lymphatic system disorders2/2891/144
PeritonitisInfections and infestations0/2891/144
Mucosal prolapse syndromeGastrointestinal disorders1/2890/144
Abdominal painGastrointestinal disorders1/2890/144
Most frequent other events
Showing 10 of 300
Most frequent other events
EventEtrasimod 2 mgPlacebo
AnaemiaBlood and lymphatic system disorders24/28914/144
HeadacheNervous system disorders24/2897/144
Colitis ulcerativeGastrointestinal disorders17/28910/144
COVID-19Infections and infestations19/2898/144
DizzinessNervous system disorders15/2891/144
PyrexiaGeneral disorders14/2896/144
ArthralgiaMusculoskeletal and connective tissue disorders13/2893/144
Abdominal painGastrointestinal disorders11/2895/144
NauseaGastrointestinal disorders9/2892/144
NasopharyngitisInfections and infestations3/2894/144

Baseline characteristics

Full Analysis Set (FAS): All randomized participants who received at least 1 dose of study treatment.

Age, Categorical
Age, Categorical(Participants)Etrasimod 2 mgPlaceboTotal
<=18 years011
Between 18 and 65 years272133405
>=65 years171027
Age, Continuous
Age, Continuous(Years)Etrasimod 2 mgPlaceboTotal
Mean41.2 ± 13.9738.9 ± 14.0440.4 ± 14.02
Sex: Female, Male
Sex: Female, Male(Participants)Etrasimod 2 mgPlaceboTotal
Female13756193
Male15288240
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Etrasimod 2 mgPlaceboTotal
Hispanic or Latino12719
Not Hispanic or Latino275136411
Unknown or Not Reported213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Etrasimod 2 mgPlaceboTotal
American Indian or Alaska Native134
Asian22931
Native Hawaiian or Other Pacific Islander000
Black or African American639
White256129385
More than one race000
Unknown or Not Reported404
08

Study locations

315 sites
  • Digestive Health Specialists of the Southeast
    Dothan, Alabama 36305, United States
  • Arizona Digestive Health
    Sun City, Arizona 85351, United States
  • Om Research, LLC
    Lancaster, California 93534, United States
  • Entertainment Medical Group, Inc.
    Los Angeles, California 90036, United States
  • United Medical Doctors
    Murrieta, California 92563, United States
  • San Diego Gastroenterology Medical Associates
    San Diego, California 92103, United States
  • ACRC Studies, LLC
    San Diego, California 92119, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80920, United States
  • Gastro Florida
    Clearwater, Florida 33761, United States
  • West Central Gastroenterology d/b/a Gastro Florida
    Clearwater, Florida 33762, United States
  • Florida Center for Gastroenterology
    Clearwater, Florida 33777, United States
  • Life Medical Center & Research, INC
    Miami Lakes, Florida 33014, United States
  • Javier Sobrado, MD
    Miami, Florida 33156, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Office of Dr Meckstroth
    Naples, Florida 34110, United States
  • NSB Research
    New Smyrna Beach, Florida 32168, United States
  • Sarkis Clinical Trials - Parent
    Ocala, Florida 34474, United States
  • IMIC, Inc.
    Palmetto Bay, Florida 33157, United States
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
  • Theia Clinical Research, LLC
    Saint Petersburg, Florida 33709, United States
  • Advanced Research Institute, Inc.
    Saint Petersburg, Florida 33710, United States
  • Lenus Research & Medical Group
    Sweetwater, Florida 33172, United States
  • USF Physicians Group
    Tampa, Florida 33606, United States
  • GCP Clinical Research
    Tampa, Florida 33609, United States
  • Guardian Angel Research Center
    Tampa, Florida 33614, United States
  • ASCLEPES Research Centers, P.C.
    Weeki Wachee, Florida 34607, United States
  • Florida Medical Clinic, P.A.
    Zephyrhills, Florida 33542, United States
  • Atlanta Gastroenterology Associates LLC
    Atlanta, Georgia 30342, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342, United States
  • Atlanta Center for Gastroenterology, P.C.
    Decatur, Georgia 30033, United States
  • Illinois Gastroenterology Group
    Gurnee, Illinois 60031, United States
  • Gen1 Research
    Moline, Illinois 61265, United States
  • Texas Digestive Disease Consultants
    Baton Rouge, Louisiana 70809, United States
  • CroNOLA
    Houma, Louisiana 70360, United States
  • Clinical Trials of SW Louisiana, LLC
    Lake Charles, Louisiana 70601, United States
  • Clinical Trials Management, LLC
    Metairie, Louisiana 70006, United States
  • Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Flint Clinical Research
    Flint, Michigan 48503, United States
  • Robert Ferguson MD
    West Bloomfield, Michigan 48323, United States
  • Gastrointestinal Associates
    Flowood, Mississippi 39232, United States
  • Sierra Clinical Research
    Las Vegas, Nevada 89106, United States
  • Las Vegas Medical Research
    Las Vegas, Nevada 89113, United States
  • Duke University Medical Center GI Clinical Research Unit
    Durham, North Carolina 27710, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Great Lakes Medical Research, LLC
    Mentor, Ohio 44060, United States
  • Care Access Research
    Poland, Ohio 44514, United States
  • Digestive Disease Specialists, Inc.
    Oklahoma City, Oklahoma 73112, United States
  • Great Lakes Medical Research, LLC
    Harrisburg, Pennsylvania 17110, United States
  • GI for Kids
    Knoxville, Tennessee 37916, United States
  • Texas Clinical Research Institute, LLC
    Arlington, Texas 76012, United States
  • Coastal Medical Group
    Baytown, Texas 77521, United States
  • Texas Gastroenterology Associates, PA
    Cypress, Texas 77429, United States
  • Texas Digestive Disease Consultants
    Dallas, Texas 76092, United States
  • Digestive Health Associates of Texas
    Garland, Texas 75044, United States
  • CliniCore Texas
    Houston, Texas 77029, United States
  • Baylor Gastroenterology Assoc
    Houston, Texas 77030, United States
  • Biopharma Informatic, Inc. Research Center
    Houston, Texas 77043, United States
  • Rio Grande Gastroenterology
    McAllen, Texas 78503, United States
  • Biopharma Informatic, Inc. Research Center
    Pasadena, Texas 77505, United States
  • Texas Digestive Disease Consultants - San Marcos
    San Marcos, Texas 78130, United States
  • Tyler Research Institute, LLC
    Tyler, Texas 75701, United States
  • Victoria Gastroenterology
    Victoria, Texas 77904, United States
  • Blue Ridge Medical Research
    Lynchburg, Virginia 24502, United States
  • Washington Gastroenterology
    Bellevue, Washington 98004, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Marshall University Department of Clinical Research
    Huntington, West Virginia 25701, United States
  • Medical College of Wisconsin Clinical Trials Office
    Milwaukee, Wisconsin 53226-0509, United States
  • Clinica Adventista Belgrano
    Caba, Buenos Aires C1430EGF, Argentina
  • Mautalen Salud e Investigacion
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1128AAF, Argentina
  • Fundación Respirar- Centro Médico Dra. De Salvo
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1426ABP, Argentina
  • CICE Sanatorio 9 de Julio
    San Miguel de Tucuman, Tucuman 4000, Argentina
  • Bankstown-Lidcombe Hospital
    Bankstown, New South Wales 2200, Australia
  • Nepean Hospital
    Kingswood, New South Wales 2747, Australia
  • Coastal Digestive Health Pty Ltd
    Maroochydore, Queensland 4558, Australia
  • Coral Sea Clinical Research Institute
    North Mackay, Queensland 4740, Australia
  • Austin Health Gastroenterology Department
    Heidelberg, Victoria 3084, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • KH der Barmherzigen Brüder Linz
    Linz, 4020, Austria
  • AKH - Medizinische Universität Wien
    Wien, 1090, Austria
  • Wilhelminenspital der Stadt Wien
    Wien, 1160, Austria
  • Institution "Gomel Regional Clinical Hospital"
    Gomel, 246029, Belarus
  • Grodno City Clinical Hospital #4
    Grodno, 230026, Belarus
  • Health Care Institution "10th City Clinical Hospital"
    Minsk, 220096, Belarus
  • Vitebsk Regional Clinical Hospital
    Vitebsk, 210037, Belarus
  • Vitebsk Regional Clinical Specialized Center
    Vitebsk, 210604, Belarus
  • AZ Sint-Lucas & Volkskliniek
    Gent, 9000, Belgium
  • UZ Gent Gastroenterology
    Gent, 9000, Belgium
  • ZNA Jan Palfijn
    Merksem, 2170, Belgium
  • AZ Delta
    Roeselare, Belgium
  • Medical center Medconsult Pleven OOD
    Pleven, 5800, Bulgaria
  • UMHAT Kanev AD, Ruse
    Ruse, 7002, Bulgaria
  • Diagnostic-Consultative Center I - Sliven, EOOD
    Sliven, 8800, Bulgaria
  • ACIBADEM CITY CLINIC TOKUDA HOSPITAL EAD,Clinical Research Center
    Sofia, 1407, Bulgaria
  • DCC "Alexandrovska", EOOD
    Sofia, 1431, Bulgaria
  • UMHAT "Sv. Ivan Rilski", EAD,Clinic of gastroenterology
    Sofia, 1431, Bulgaria
  • UMHAT Tsaritsa Yoanna-ISUL EAD
    Sofia, 1527, Bulgaria
  • UMHATEM "N.I.Pirogov" EAD, Gastroenterology Department/Clinical Research center, next to the chimney
    Sofia, 1606, Bulgaria
  • Diagnostic Consultation Center CONVEX EOOD
    Sofia, 1680, Bulgaria
  • Acibadem City Clinic University Hospital EOOD
    Sofia, 1784, Bulgaria
  • Medical Center Nov Rehabilitatsionen Tsentar EOOD
    Stara Zagora, 6000, Bulgaria

Showing the first 100 of 315 sites across 40 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Feb 2022, 31 months.

Results were first posted in Dec 2022, 10 months after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 31 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2019
First posted
May 10, 2019
StartActual
Jun 13, 2019
Primary completionActual
Feb 8, 2022
CompletionActual
Feb 16, 2022
Results first posted
Dec 20, 2022
Last update
Dec 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03945188
Responsible party
Sponsor
First posted
May 10, 2019
Start date
Jun 13, 2019
Primary completion
Feb 8, 2022
Completion
Feb 16, 2022
Results posted
Dec 20, 2022
Last update
Dec 20, 2022

Study contacts

Arena CT.gov Administrator
study director · Arena Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion